Drug Profile
Research programme: interleukin-10 gene therapeutics - Xalud Therapeutics
Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Xalud Therapeutics
- Class Gene therapies; Interleukins
- Mechanism of Action Interleukin-10 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for research development in Neurological-disorders in USA (Parenteral)
- 16 Dec 2013 Early research in Neurological disorders in USA (Parenteral)